Strategic treatment pause of first-line immune checkpoint inhibitor + VEGFR-tyrosine kinase inhibitor in patients with good or intermediate risk metastatic renal cell carcinoma (mRCC) in response at 1 year of treatment (SPICI-GETUG R05): A non-inferiority randomized clinical trial.

Marine Gross-Goupil,Felix Lefort,Eric Frison,Julien Asselineau,Laurence Albiges,Mathieu Larroquette,Alain Ravaud

doi:10.1200/jco.2024.42.4_suppl.tps487

Strategic treatment pause of first-line immune checkpoint inhibitor + VEGFR-tyrosine kinase inhibitor in patients with good or intermediate risk metastatic renal cell carcinoma (mRCC) in response at 1 year of treatment (SPICI-GETUG R05): A non-inferiority randomized clinical trial.

Marine Gross-Goupil, Felix Lefort + Show 5 more

https://doi.org/10.1200/jco.2024.42.4_suppl.tps487

Copy DOI

Export

Save

Cite

Journal: Journal of Clinical Oncology

Publication Date: Feb 1, 2024

Affiliation: University of Bordeaux

#Intermediate Risk Metastatic Renal Cell #Risk Metastatic Renal Cell Carcinoma #Non-inferiority Randomized Clinical Trial #Kinase Inhibitor In Patients #VEGFR-tyrosine Kinase Inhibitor #Non-inferiority Clinical Trial #Non-inferiority Trial #Intermediate Cell #Randomized Trial #First-line Immune Checkpoint Inhibitor

Abstract
Full-Text
Similar Papers

Abstract

Listen

Strategic treatment pause of first-line immune checkpoint inhibitor + VEGFR-tyrosine kinase inhibitor in patients with good or intermediate risk metastatic renal cell carcinoma (mRCC) in response at 1 year of treatment (SPICI-GETUG R05): A non-inferiority randomized clinical trial.

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

Strategic treatment pause of first-line immune checkpoint inhibitor + VEGFR-tyrosine kinase inhibitor in patients with good or intermediate risk metastatic renal cell carcinoma (mRCC) in response at 1 year of treatment (SPICI-GETUG R05): A non-inferiority randomized clinical trial.